Stockholm, 2013-01-21 08:30 CET (GLOBE NEWSWIRE) -- PledPharma (STO: PLED) announced today that their PledOx™ Phase IIb clinical trial, PLIANT, is approved by the U.S. Food and Drug Administration (FDA). The goal of the PLIANT study is that pretreatment with PledOx reduces serious side effects of the chemotherapy FOLFOX in patients treated for advanced colorectal cancer.
